Tuesday, March 24, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

After 25 years in the dark, the CDC wants to study the true toll of guns in America

The uniquely American epidemic of mass killings by firearms grabs most of the attention from the media, politicians and the public. And the big increase in homicides in 2020 and overall violent crime — on the rise across many American cities — also get their share of coverage.

But for decades, the devastating impact of nonfatal firearm injuries in the U.S. has been understudied, undercovered by the media and often overlooked. Political pressure from the gun lobby, regulations and “disordered and highly segmented” collection systems have created chronically unreliable data and information that obscure our true understanding of the public health, financial, psychological and social toll of gun injuries, according to a 2020 study on firearms.

We know from Centers for Disease Control and Prevention data that just over 100 people, on average, are killed by firearms in the U.S. every day. That includes crimes, suicides, gun accidents and shootings involving law enforcement.

Source: NPR

https://www.npr.org/2021/09/29/1039907305/cdc-study-toll-guns-america

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!